Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04479020
Previous Study | Return to List | Next Study

REcanalization of Distal Cerebral Vessels In Acute Stroke Using ApeRio®

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04479020
Recruitment Status : Active, not recruiting
First Posted : July 21, 2020
Last Update Posted : July 21, 2020
Sponsor:
Information provided by (Responsible Party):
Acandis GmbH

Brief Summary:
The purpose of the Aperio® PMCFU is to collect data in clinical practice of the Aperio® and Aperio® Hybrid Device, which is intended to restore blood flow in the neurovasculature by removing thrombus in patients, experiencing ischemic stroke. Recanalisation status will be assessed at the end of the procedure using the modified TICI (Thrombolysis in cerebral infarction) score.

Condition or disease Intervention/treatment
Acute Stroke Device: Mechanical Thrombectomy

Detailed Description:

Study Type: prospective, multicenter, single-arm, open-label Participants: 10 participating centers in Germany planned PI: Dr. Franziska Dorn, University Hospital Munich, Germany Estimated Enrolment: A minimum of 130 patients treated with the Aperio® or Aperio® Thrombectomy Device due to thrombotic occlusion of the anterior or posterior circulation arteries with a diameter <3mm

Follow up: 3 months Estimated Final Assessment: End of 2022

This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up Study to collect comprehensive information on technical and clinical success and safety of the use of Aperio® and Aperio® Hybrid Thrombectomy Device in arteries <3mm in clinical practice. Aperio® and Aperio® Hybrid Thrombectomy Device will be used within its approved indication.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 130 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Months
Official Title: REcanalization of Distal Cerebral Vessels In Acute Stroke Using ApeRio®
Actual Study Start Date : July 1, 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : January 2022

Intervention Details:
  • Device: Mechanical Thrombectomy
    Mechanical thrombectomy requiring the use an Aperio® or Aperio® Hybrid Thrombectomy device due to an thrombotic occlusion in the anterior and posterior circulation arteries with a diameter <3mm


Primary Outcome Measures :
  1. Safety and Efficacy [ Time Frame: Immediatley after interventional procedure ]

    Successful arterial recanalization of occluded target vessel measured by mTICI score of 2b or 3 following the use of the Aperio® and Aperio® Hybrid Thrombectomy Device without any symptomatic intracranial hemorrhage and rescue therapy within 3 passes per Device.

    mTICI describes the response of thrombolytic therapy in ischemic stroke. Higashida et al. 2003: Grade 0: no perfusion Grade 1: penetration with minimal perfusion Grade 2: partial perfusion Grade 2A: only partial filling (less than two-thirds) of the entire vascular territory is visualized Grade 2B: complete filling of all of the expected vascular territory is visualized but the filling is slower than normal Grade 3: complete perfusion


  2. Neurological Outcome [ Time Frame: Immediately after interventional procedure ]

    Neurological outcome assessed by mRS (modified Ranking Scale)= 0-2 0 No Symptoms

    1. No significant disability, despite symptoms, able to perform all usual duties and activities
    2. Slight disability; unable to perform all previous activities but able to look after own affairs without assistance
    3. Moderate disability; requires some help, but able to walk without assistance
    4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
    5. Severe disability bedridden incontinent and requires constant nursing care and attention
    6. Patient died


Secondary Outcome Measures :
  1. Good neurological outcome [ Time Frame: at 90 days(+-10 days) ]

    mRS (modified Ranking Scale)= 0-2

    0 No Symptoms

    1. No significant disability, despite symptoms, able to perform all usual duties and activities
    2. Slight disability; unable to perform all previous activities but able to look after own affairs without assistance
    3. Moderate disability; requires some help, but able to walk without assistance
    4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
    5. Severe disability bedridden incontinent and requires constant nursing care and attention
    6. Patient died



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients treated with an Aperio® or Aperio® Hybrid Thrombectomy Device due to a thrombotic occlusion in the anterior and posterior circulation arteries with a vessel diameter <3mm.
Criteria

Inclusion Criteria:

  • Any patient treated according to IFU with the Aperio® or Aperio® Hybrid Thrombectomy Device due to occlusion in arteries <3mm of the anterior or posterior circulation
  • Age ≥ 18 years

Exclusion Criteria:

  • pre stroke mRS ≥ 3
  • Any contraindication according to IFU

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04479020


Locations
Layout table for location information
Germany
Klinikum der Ludwig-Maximilian-Universität München
München, Germany, 81377
Sponsors and Collaborators
Acandis GmbH
Layout table for additonal information
Responsible Party: Acandis GmbH
ClinicalTrials.gov Identifier: NCT04479020    
Other Study ID Numbers: REVISAR
First Posted: July 21, 2020    Key Record Dates
Last Update Posted: July 21, 2020
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases